ClinicalTrials.gg
RecruitingNCT07720882"Triple-F" BCIUpdated Jul 22, 2026

A Clinical Study of a Fully Implanted, Wireless and Functional BCI for Upper-Limb Functional Replacement in Tetraplegia Due to Spinal Cord Injury: Efficacy and Safety

An interventional study of "Triple-F" BCI in Spinal Cord Injury, sponsored by NeuroXess Technology (shanghai) Co.,Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by NeuroXess Technology (shanghai) Co.,Ltd. · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Spinal Cord Injuries with a site in China — 26 open to participants now, 32 under way, none of them phase 3. Spinal Cord Injuries · China.

Planned enrollment
40th of 71
32 · median 36
Started
2026
with 8 others
No phase
44 of 80
22 open now
Primary completion
2027-01
later than 15 of 31 live
Registered
74th of 80
by date

Among the 80 studies in Spinal Cord Injuries with a site in China, this one is the 40th largest by planned enrollment of the 71 interventional ones that give a count, is one of 9 that started in 2026, is one of 44 with no phase, reaches primary completion later than 15 of the 31 other live ones, and was the 74th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

26 of the 80 studies in Spinal Cord Injuries with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Spinal Cord Injuries with a site in China, or all of them as a file.
02

Study summary

This prospective, multicenter, single-arm clinical trial will enroll subjects with tetraplegia secondary to spinal cord injury. An implantable brain-computer interface system for compensatory hand motor function will be used to reconstruct upper-limb function, so as to evaluate the safety and clinical efficacy of this device in achieving upper-limb functional replacement.

Read the detailed description

This trial adopts a prospective, multicenter, single-arm target value study design.

All enrolled subjects will receive implantation of an implantable brain-computer interface system for compensatory hand motor function, followed by standardized brain-computer training (including brain-controlled pneumatic gloves). Follow-up assessments will be conducted at 1, 2, 3 and 6 months after implantation to evaluate the safety and efficacy of the investigational medical device for upper-limb functional replacement in patients with tetraplegia caused by spinal cord injury.

03

Conditions studied

  • Spinal Cord Injury

Keywords

  • BCI
  • Spinal Cord Injury
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years ≤ age ≤ 65 years, male or female;
  • Cervical spinal cord injury (injury level C2-C6), with ASIA Impairment Scale grade A, B, or C;
  • Severe impairment of hand function on the target upper extremity: finger flexor muscle strength \< grade 3 as assessed by the ISNCSCI scale;
  • ARAT score ≥ 2 for "hand to mouth"; score ≥ 1 for both "hand to top of head" and "hand to back of head"; and scores ≤ 1 for each of the grasp, grip, and pinch tasks;
  • Neurological assessment confirms normal motor-related cortical function of the brain, with no acute cerebral functional changes;
  • At least 12 months have elapsed since the cervical spinal cord injury resulting in tetraplegia, and the condition has been stable for at least 6 months following standardized treatment (with documentation of rehabilitation therapy records available);
  • Good cognitive function: (MMSE) score ≥ 22 and Montreal Cognitive Assessment (MoCA) score ≥ 26 ;
  • Possess the basic visual, auditory, and language comprehension abilities required for interaction, and be able to cooperate with training;
  • The subject voluntarily participates and is willing to comply with the relevant examinations and follow-up visits.

Exclusion criteria

Exclusion Criteria:

  • Neurodegenerative diseases / secondary injury due to tumors, or severe autonomic dysreflexia;
  • Presence of intracranial lesions or to intracranial implantation: active epilepsy or definite epileptogenic tendency; severe cerebrovascular disease; brain tumor; moderate-to-severe sequelae of traumatic brain injury; space-occupying lesions or structural abnormalities at the electrode implantation target area; already implanted with active implantable electronic devices such as cardiac pacemakers/defibrillators, cochlear implants, deep brain stimulators, or drug infusion pumps, or presence of local metal foreign bodies/implants in the area to be implanted; or other contraindications to intracranial implantation as assessed by the investigator;
  • in other organ systems;
  • Cardiovascular system diseases: severe cardiac insufficiency, severe arrhythmias, or uncontrolled hypertension;
  • Other ongoing medical interventions that may affect the benefit from BCI intervention (e.g., dependence on ventilator support, tracheostomy, nasogastric tube feeding, etc.);
  • Presence of psychiatric or psychological disorders that may interfere with the subject's participation in BCI training, such as depression (HAMD ≥ 18 points) or anxiety disorder (HAMA ≥ 14 points) ;
  • Presence of active infection; severe coagulation abnormalities ( (APTT) or prothrombin time (PT) > 2.5 × ); or other severe systemic diseases that, as assessed by the investigator, may significantly increase surgical risk or interfere with neurological function assessment or system use;
  • Contraindications to surgery or anesthesia, or deemed unsuitable for implantation surgery by anesthesiology/surgical assessment;
  • Fever, or vital signs and/or intracranial status not yet stabilized;
  • Upper-limb motor dysfunction due to other etiologies, such as amyotrophic lateral sclerosis, syringomyelia, spinal vascular diseases, muscular dystrophy, hypokalemic periodic paralysis, spondylitis, arthritis, osteomyelitis, peripheral nerve injury, tendon rupture, etc.;
  • Planned MRI examination during the device implantation period;
  • \< 6 months (e.g., severe end-stage diseases);
  • Participation in other drug or medical device clinical trials within the past 1 month;
  • Pregnant or breastfeeding women;
  • Other conditions that, in the investigator's judgment, make the subject unsuitable for participation in this clinical trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    "Triple-F" BCI

    Experimental: Implantation of the "Triple-F" BCI

    Device: "Triple-F" BCI

Interventions

  • Device"Triple-F" BCI

    Subjects will undergo implantation of the "Triple-F" BCI and receive standardized brain-computer interface training postoperatively, including training with brain-controlled pneumatic gloves. Follow-up visits will be scheduled at 1, 2, 3 and 6 months after implantation.

    Also known as: Fully implanted, wireless and functional BCI

06

What researchers measure

Primary outcomes

  1. BCI-assisted ARAT response rate (at 3 months postoperatively)

    The proportion of subjects whose BCI-assisted ARAT score at 3 months postoperatively minus the baseline unassisted ARAT score at screening is ≥ the Minimal Clinically Important Difference (MCID).

    Time frame: 3 months post-operation

Secondary outcomes

  1. The ARAT score assessed with BCI assistance

    The subject, wearing the pneumatic glove paired with the BCI system, performs the four ARAT subscales (grasp, grip, pinch, and gross motor) sequentially per standard procedures, with each subscale score and the total ARAT score recorded.The unabridged scoring sheet is titled the "Action Research Arm Test Scoring Sheet" . It yields a minimum score of 0 and a maximum score of 57 per arm (19 items scored 0-3 each), with higher scores indicating better outcomes, that is, better arm motor status.

    Time frame: 2, 3, and 6 months post-operation

  2. ARAT score assessed without BCI assistance

    The subject completes the assessment in accordance with the standard ARAT operating procedures without using the BCI-actuated pneumatic glove.The unabridged scoring sheet is titled the "Action Research Arm Test Scoring Sheet" . It yields a minimum score of 0 and a maximum score of 57 per arm (19 items scored 0-3 each), with higher scores indicating better outcomes, that is, better arm motor status.

    Time frame: baseline, 3 and 6 months post-operation

  3. Task completion rate of five common hand-movement brain-control tasks

    Time frame: baseline,2,3 and 6 months post-operation

  4. Success rate for six-direction target selection under brain control

    Time frame: 3 and 6 months post-operation

  5. Change from baseline in Activities of Daily Living (ADL) score as measured by the Barthel Index

    The Activities of Daily Living (ADL) Scale, commonly known as the Barthel Index, is scored using its original, unabridged form titled the "Barthel Index" , which comprises 10 items covering basic self-care and mobility, yielding a minimum total score of 0 (complete dependence) and a maximum of 100, with higher scores indicating better outcomes-that is, greater independence in activities of daily living.

    Time frame: baseline,2, 3 and 6 months post-operation

  6. Change from baseline in the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) score

    ISNCSCI are recorded on its standard worksheet titled the "International Standards for Neurological Classification of Spinal Cord Injury" (ASIA/ISNCSCI worksheet), in which sensory function is scored separately for light touch and pin prick (each ranging from a minimum of 0 to a maximum of 112 across 28 dermatomes bilaterally) and motor function is scored across 10 key muscle groups per side (yielding a total motor score from 0 to 100, with upper- and lower-extremity subscores of 0-50 each), with higher scores indicating better outcomes-that is, less neurological impairment after spinal cord injury.

    Time frame: baseline, 2,3 and 6 months post-operation

  7. Reliability of the device

    Under standardized conditions (with the subject at rest and room temperature ), the number of well-functioning channels of the implanted device is evaluated and recorded, together with the mean, median, minimum, and maximum impedance of the well-functioning channels and their trends over time. Impedance trends over time are presented as line graphs. Channels with an impedance not exceeding 1 MΩ are classified as well-functioning.

    Time frame: day of implantation,1,2,3 and6 months post-operation

  8. Investigator-evaluated device operability performance

    At the scheduled visits, the operating investigator rates the following performance items of the BCI compensation system using a pre-designed device performance evaluation form, graded on a four-level scale (excellent/good/fair/poor): signal acquisition stability, defined as the reliability and consistency of electrode signal recording; decoding response speed, defined as the latency from the generation of motor intention to the initiation of pneumatic glove movement; pneumatic glove output accuracy, defined as the degree of concordance between the movements actually performed by the glove and the decoded intentions; overall system stability, defined as the failure rate and system reliability during long-term use; wearing comfort and convenience, defined as the ease of donning the pneumatic glove and the subject's comfort while wearing it; and overall operational convenience, defined as the complexity of routine system operation and its user-friendliness.

    Time frame: 3 and 6 months post-operation

  9. Subject-reported evaluation of device use

    Assessment method: A subject device-use satisfaction questionnaire is administered; at the scheduled visits, the investigator reads each questionnaire item aloud to the subject, the subject responds verbally, and the investigator records the answers verbatim . The investigator must not guide or suggest the subject's answers in any way, and upon completion must confirm with the subject that the recorded responses are consistent with his or her own opinions. The questionnaire covers the following dimensions, each scored on a 5-point Likert scale with the following criteria: 5 = very satisfied / very easy, 4 = satisfied / relatively easy, 3 = neutral / neutral, 2 = dissatisfied / relatively difficult, 1 = very dissatisfied / very difficult. The dimensions include: wearing comfort, defined as the comfort of wearing the pneumatic glove in daily use; donning and doffing convenience, defined as the ease of putting on and taking off the pneumatic glove independent.

    Time frame: 3 and 6 months post-operation

  10. Average time of device use per month

    Time frame: 3 and 6 months post-operation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jan 2027, 6 months after the start.

Of 49 industry-sponsored interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 6 months is below that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2026
First posted
Jul 22, 2026
StartActual
Jul 7, 2026
Primary completionEst.
Jan 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07720882
Lead sponsor
NeuroXess Technology (shanghai) Co.,Ltd.
Collaborators
Huashan Hospital
Responsible party
Sponsor
First posted
Jul 22, 2026
Start date
Jul 7, 2026
Primary completion
Jan 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Jul 22, 2026

Study contacts

Ying Mao, MD
Contact
maoying@fudan.edu.cn
+86 021 5288 8045
Liang Chen, MD
Contact
hschenliang@fudan.edu.cn

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion